Arveux P, Benard S, Bouee S, Lafuma A, Martin L, Cravello L, Remy V, Breugelmans JG (2007) Invasive cervical cancer treatment costs in France. Bull Cancer 94(2):219–224
Beby-Defaux A, Bourgoin A, Ragot S, Battandier D, Lemasson JM, Renaud O, Bouguermouh S, Vienne Md ML, Agius G (2004) Human papillomavirus infection of the cervix uteri in women attending a Health Examination Center of the French social security. J Med Virol 73(2):262–268
Bergeron C, Breugelmans JG, Bouee S, Lorans C, Benard S, Remy V (2006) Co ˆt du depistage et de la prise en charge des lesions precancereuses du col uterin en France. Gynecologie Obstetrique Fertilite 34(11):1036–1042
Bergeron C, Largeron N, McAllister R, Mathevet P, Remy V (2008) Cost-effectiveness analysis of the introduction of a quadrivalent human papillomavirus vaccine in France. Int J Technol Assess Health Care 24(1):10–19
Bosch FX, Lorincz A, Munoz N, Meijer CJ, Shah KV (2002) The causal relation between human papillomavirus and cervical cancer. J Clin Pathol 55(4):244–265
Boulanger JC, Sevestre H, Bauville E, Ghighi C, Harlicot JP, Gondry J (2004) Epidemiology of HPV infection. Gynecol Obstet Fertil 32(3):218–223
Clavel C, Masure M, Bory JP, Putaud I, Mangeonjean C, Lorenzato M, Nazeyrollas P, Gabriel R, Quereux C, Birembaut P (2001) Human papillomavirus testing in primary screening for the detection of high-grade cervical lesions: a study of 7932 women. Br J Cancer 84(12):1616–1623
Clifford GM, Smith JS, Plummer M, Munoz N, Franceschi S (2003) Human papillomavirus types in invasive cervical cancer worldwide: a meta-analysis. Br J Cancer 88(1):63–73
Cochand-Priollet B, Vincent S, Vielh P (2004) Cytopathology in France. Cytopathology 15(3):163–166
Coleman MP, Gatta G, Verdecchia A, Esteve J, Sant M, Storm H, Allemani C, Ciccolallo L, Santaquilani M, Berrino F (2003) EUROCARE-3 summary: cancer survival in Europe at the end of the 20th century. Ann Oncol 14(Suppl 5):v128–v149
Dalstein V, Riethmuller D, Sautiere JL, Pretet JL, Kantelip B, Schaal JP, Mougin C (2004) Detection of cervical precancer and cancer in a hospital population; benefits of testing for human papillomavirus. Eur J Cancer 40(8):1225–1232
Debicki D, Ferko N, Demarteau N, Gallivan S, Bauch C, Anonychuk A, Mantovani L, Capri S, Chou CY, Standaert B, Annemans L (2008) Comparison of detailed and succinct cohort modelling approaches in a multi-regional evaluation of cervical cancer vaccination. Vaccine 26(Suppl 5):F16–F28
Exbrayat C (2002) Col de l’ut  ́rus. In: Remontet L, Buemi A, Velten M, Jougla E, Esteve J (eds) Evolution de l’incidence et de la mortalit  ́ par cancer en France de 1978 ` 2000. Institut de Veille Sanitaire. Departement Maladies Chroniques et Traumatismes, Saint-Maurice C  ́dex, pp 107–112
Fahey MT, Irwig L, Macaskill P (1995) Meta-analysis of Pap test accuracy. Am J Epidemiol 141(7):680–689
Ferlay J, Bray F, Pisani P, Parkin DM (2004) Globocan 2002: Cancer incidence, mortality and prevalence worldwide. IARC Press. Available via IARC. Accessed August 2008
Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM (2010) GLOBOCAN 2008: Cancer incidence and mortality worldwide. International agency for research on cancer. Available via 
Gold MR, Franks P, McCoy KI, Fryback DG (1998) Toward consistency in cost-utility analyses: using national measures to create condition-specific values. Med Care 36(6):778–792
Goldie SJ, Weinstein MC, Kuntz KM, Freedberg KA (1999) The costs, clinical benefits, and cost-effectiveness of screening for cervical cancer in HIV-infected women. Ann Intern Med 130(2):97–107
Goldie SJ, Kohli M, Grima D, Weinstein MC, Wright TC, Bosch FX, Franco E (2004) Projected clinical benefits and cost-effectiveness of a human papillomavirus 16/18 vaccine. J Natl Cancer Inst 96(8):604–615
Harper DM, Franco EL, Wheeler CM, Moscicki AB, Romanowski B, Roteli-Martins CM, Jenkins D, Schuind A, Costa-Clemens SA, Dubin G (2006) Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomized control trial. Lancet 367(9518):1247–1255
Insinga R, Glass A, Rush B. (2005) Health state transitions following an abnormal pap smear: implications for health utility assessment in cost-effectiveness analyses. (Abstract W-02 presented at 22nd International Papillomavirus Conference and Clinical Workshop 2005, Vancouver, Canada, April 30–May 6)